

Successful phase IIB trial with third-generation grass pollen allergy vaccine BM32

26 January 2017

Biomay, a global leader in allergy immunotherapy, announced today that a second Phase IIb study (clinicaltrials.gov identifier NCT02643641) has been successfully completed with its third generation grass pollen allergy vaccine BM32. The study was designed to demonstrate the optimal dose regimen to induce an allergen-specific IgG immune response. Correlation of the immunological effects with the alleviation of allergy symptoms in the subsequent grass pollen season was another important objective of the trial.

The study reached its primary endpoint: it was observed that a regimen of five monthly injections of 80 µg of BM32 was statistically significantly superior to all other dosing schemes in terms of induction of [allergen](#) specific IgG4 (p

APA citation: Successful phase IIB trial with third-generation grass pollen allergy vaccine BM32 (2017, January 26) retrieved 26 November 2022 from <https://medicalxpress.com/news/2017-01-successful-phase-iib-trial-third-generation.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.